Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotic trial aims to stop COPD attacks by targeting hidden fungus

NCT ID NCT07665359

Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 4-week course of the antibiotic TMP-SMX (Bactrim) can reduce the number of serious COPD flare-ups in people whose lungs carry Pneumocystis jirovecii, a common fungus. Researchers will compare the antibiotic to a placebo in 630 adults with advanced COPD who have had at least one flare-up in the past year. Participants will be followed for one year to track flare-ups and lung function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Trimethoprim-Sulfamethoxazole (TMP-SMX), also known as Bactrim or Sulfatrim
What this could lead to
If it works, this could point toward a new way to prevent COPD flare-ups by treating a hidden infection in the lungs.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. The antibiotic may not clear the fungus or reduce flare-ups, and could cause side effects like allergic reactions or antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 630 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40 and above，male or female； * COPD who meet the diagnostic criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 ( post-bronchodilator FEV1/forced vital capacity \[FVC\] ratio \< 0.7 and post-bronchodilator FEV1% predicted ≥ 30%), and have documented history of high exacerbation risk (Group E, defined as exacerbation history of ≥ 1 moderate or severe acute exacerbation within 12 months prior to inclusion)； * Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to inclusion; Double therapy (LABA + LAMA) allowed if ICS is contraindicated； * PCR detection of Pneumocystis jirovecii in induced sputum is positive； * Informed consent Exclusion Criteria: * Allergic to TMP, SMX or sulfonamide drugs； * There are pneumonia or other infections that require long-term use of antibacterial drugs (such as tuberculosis, NTM, other fungi, etc.)； * Having used antibiotics within the previous 4 weeks prior to screening； * Experience of AECOPD events within the previous 4 weeks prior to screening; * Having a definite immunodeficiency disorder or receiving immunosuppressive therapy (such as HIV, agranulocytosis, solid organ or hematopoietic stem cell transplantation, malignant tumors, using long-term high-dose hormones \> 20mg/day prednisone equivalent for more than 4 weeks)； * Severe liver and kidney dysfunction (ALT/AST \> 3 times the upper limit of normal value, eGFR \< 60 mL/min/1.73m²)； * Pregnant, lactating women or those planning to become pregnant; * Folic acid deficiency-induced microcytic anemia; * Currently using coumarin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide or glibenclamide; * Currently participating in other interventional clinical studies；

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Jiaxing University

    Jiaxing, Zhejiang, China

  • First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • First Affiliated Hospital of Zhejiang University

    Hangzhou, Zhejiang, China

  • Huzhou Central Hospital

    Huzhou, Zhejiang, China

  • Lishui hospital of Zhejiang University

    Lishui, Zhejiang, China

  • Red Cross Hospital, Hangzhou, China

    Hangzhou, Zhejiang, China

  • Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Shanghai Pulmonary Hospital, Shanghai, China

    Shanghai, Shanghai Municipality, China

  • Shanghai Tongji Hospital, Tongji University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shaoxing People's Hospital

    Shaoxing, Zhejiang, China

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, China

  • Taizhou Hospital

    Taizhou, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

    Taizhou, Zhejiang, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of Wenzhou Medical University

    Lishui, Zhejiang, China

  • Tongji Hospital

    Wuhan, Hubei, China

  • West China Hospital

    Chengdu, Sichuan, China

  • Zhejiang Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Quhua Hospital

    Quzhou, Zhejiang, China

  • Zhejiang Rongjun Hospital

    Jiaxing, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.